Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-10 pm EST			Pre-market 07:30:08 pm
29.03 ^USD	+2.80%		28.72	-1.09%

Dec. 09	FDA probes deaths likely related to COVID vaccines across age groups	RE
Dec. 09	Fda probes if Covid shots might be linked to deaths of adults - Bloomberg News	RE

Moderna to Supply COVID-19 Vaccines in EU, Norway

Published on 01/24/2025 at 08:04 am EST - Modified on 01/24/2025 at 08:06 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Dec. 09	FDA probes deaths likely related to COVID vaccines across age groups	RE
Dec. 09	Fda probes if Covid shots might be linked to deaths of adults - Bloomberg News	RE
Dec. 04	AI's rise stirs excitement, sparks job worries	RE
Dec. 02	Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11:00 AM
Dec. 01	Trading Day: World shivers on Japan rate chill	RE
Dec. 01	Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval	MT
Dec. 01	Moderna Falls As FDA Vows To Impose New Vaccine Rules	MT
Dec. 01	UK Gains Zero-Tariff Access for Medicines Under New US Trade Pact	MT
Nov. 26	Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating	MT
Nov. 24	Moderna, Inc. Enters into Credit Agreement	CI
Nov. 24	Moderna, Inc. - Analyst/Investor Day
Nov. 24	Phenomenal Value Destruction at Moderna
Nov. 24	Moderna presents pipeline progress and 3-year strategy
Nov. 21	Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating	MT
Nov. 21	Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating	MT
Nov. 21	RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating	MT
Nov. 21	Wolfe Research Adjusts Price Target on Moderna to $17 From $16, Maintains Underperform Rating	MT
Nov. 21	Still Not Enough
Nov. 21	Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix…
Nov. 20	Health Care Down, But not by Much, Amid Deal Activity -- Health Care Roundup	DJ
Nov. 20	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Nov. 20	Sector Update: Health Care Stocks Lower Thursday Afternoon	MT
Nov. 20	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
Nov. 20	Moderna Expects 10% Revenue Growth Next Year	MT
Nov. 20	Moderna Closes $1.5 Billion Loan Facility From Ares Management	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company